Abstract
Temperature-induced changes of affinity and efficacy of the α2-adrenoceptor full agonist UK14,304 and the partial agonists clonidine and guanfacine were investigated to elucidate the mechanism of partial agonism at the terminal α2-autoreceptor. The effect of temperature on the efficacy of the substances was tested in 3H-noradrenaline release experiments at 37°C and at room temperature. Human neocortical slices were prelabeled with 3H-noradrenaline, superfused, and stimulated electrically under autoinhibition-free conditions. Furthermore, saturation binding experiments with human neocortical synaptosomes were performed at 37°C and 17°C to evaluate the influence of temperature on the affinity of 3H-clonidine and 3H-UK14,304. Temperature-induced changes of the association and dissociation rate constants of 3H-UK14,304 and 3H-clonidine were assessed in corresponding kinetic binding experiments. Our experiments reveal that clonidine and guanfacine lose efficacy when the temperature is lowered, whereas no change was noted for the full agonist UK14,304. Moreover, the affinity of clonidine and guanfacine was shown to decrease at lower temperature. Kinetic experiments indicated that the loss of affinity observed for 3H-clonidine at 17°C is due to a marked reduction of the association rate. The loss of efficacy of the partial agonists is most likely related to the short binding duration; partial agonists do not bind long enough to the receptor to mediate a maximum response. The discrepancy between the time required to elicit a maximum response and the actual binding time may be greater for partial agonists at lower temperatures, thus, causing the intrinsic activity to decline.
Similar content being viewed by others
References
Andorn AC, Carlson MA, Gilkeson RC (1988) Specific [3H]UK 14,304 binding in human cortex occurs at multiple high affinity states with α2-adrenergic selectivity and differing affinities for GTP. Life Sci 43:1805–1812
Bylund DB, Murrin LC (2000) Radioligand saturation binding experiments over large concentration ranges. Life Sci 67:2897–2911
Cash R, Raisman R, Ruberg M, Agid Y (1985) Adrenergic receptors in frontal cortex in human brain. Eur J Pharmacol 108:225–232
Dalpiaz A, Scatturin A, Varani K, Pecoraro R, Pavan B, Borea PA (2000) Binding thermodynamics and intrinsic activity of adenosine A1 receptor ligands. Life Sci 67:1517–1524
Feuerstein TJ, Limberger N (1999) Mathematical analysis of the control of neurotransmitter release by presynaptic receptors as a supplement to experimental data. Naunyn-Schmiedeberg’s Arch Pharmacol 359:345–359
Feuerstein TJ, Dooley DJ, Seeger W (1990) Inhibition of norepinephrine and acetylcholine release from human neocortex by ω-Conotoxin GVIA. J Pharmacol Exp Ther 252:778–785
Feuerstein TJ, Huber B, Vetter J, Aranda H, Van Velthoven V, Limberger N (2000) Characterization of the α2-adrenoceptor subtype, which functions as α2-autoreceptor in human neocortex. J Pharmacol Exp Ther 294:356–362
Ghanouni P, Gryczynski Z, Steenhuis JJ, Lee TW, Farrens DL, Lakowicz JR, Kobilka BK (2001) Functionally different agonists induce distinct conformations in the G protein coupling domain of the β2 adrenergic receptor. J Biol Chem 276:24433–24436
Hein P, Rochais F, Hoffmann C, Dorsch S, Nikolaev VO, Engelhardt S, Berlot CH, Lohse MJ, Bunemann M (2006) Gs activation is time-limiting in initiating receptor-mediated signaling. J Biol Chem 281:33345–33351
Jasper JR, Insel PA (1992) Evolving concepts of partial agonism. The beta-adrenergic receptor as a paradigm. Biochem Pharmacol 43:119–130
Jin R, Banke TG, Mayer ML, Traynelis SF, Gouaux E (2003) Structural basis for partial agonist action at ionotropic glutamate receptors. Nat Neurosci 6:803–810
Kenakin T (2002) Drug efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 42:349–379
Kenakin T (2004) Principles: receptor theory in pharmacology. Trends Pharmacol Sci 25:186–192
Kilpatrick GJ, el Tayar N, Van de Waterbeemd H, Jenner P, Testa B, Marsden CD (1986) The thermodynamics of agonist and antagonist binding to dopamine D-2 receptors. Mol Pharmacol 30:226–234
Koshland DE Jr., Nemethy G, Filmer D (1966) Comparison of experimental binding data and theoretical models in proteins containing subunits. Biochemistry 5:365–385
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275
Monod J, Wyman J, Changeux JP (1965) On the nature of allosteric transitions: a plausible model. J Mol Biol 12:88–118
Nikolaev VO, Hoffmann C, Bunemann M, Lohse MJ, Vilardaga JP (2006) Molecular basis of partial agonism at the neurotransmitter α2A-adrenergic receptor and Gi-protein heterotrimer. J Biol Chem 281:24506–24511
Paris H, Galitzky J, Senard JM (1989) Interactions of full and partial agonists with HT29 cell alpha 2-adrenoceptor: comparative study of [3H]UK-14,304 and [3H]clonidine binding. Mol Pharmacol 35:345–354
Ross EM (1996) Pharmacodynamics. Mechanisms of drug action and the relationship between drug concentration and effect. In: Goodman, Gilman’s The pharmacological basis of therapeutics, J.G. Hardman, L.E. Limbird (eds.), The McGraw-Hill Companies 9th edn. pp 29–41
Seifert R, Wenzel-Seifert K, Gether U, Kobilka BK (2001) Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations. J Pharmacol Exp Ther 297:1218–1226
Steffens M, Olayioye A, Huber B, Allgaier C, Feuerstein TJ (2005) Does the binding duration of a partial α2-adrenoceptor agonist exceed its activation interval at the autoreceptor? Int J Pharmacol 1:299–310
Stephenson RP (1956) A modification of receptor theory. Br J Pharmacol Chemother 11:379–393
Stickle D, Barber R (1989) Evidence for the role of epinephrine binding frequency in activation of adenylate cyclase. Mol Pharmacol 36:437–445
Vilardaga JP, Bunemann M, Krasel C, Castro M, Lohse MJ (2003) Measurement of the millisecond activation switch of G protein-coupled receptors in living cells. Nat Biotechnol 21:807–812
Vrbjar N, Kean KT, Szabo A, Senak L, Mendelsohn R, Keough KM (1992) Sarcoplasmic reticulum from rabbit and winter flounder: temperature-dependence of protein conformation and lipid motion. Biochim Biophys Acta 1107:1–11
Weiland GA, Minneman KP, Molinoff PB (1979) Fundamental difference between the molecular interactions of agonists and antagonists with the beta-adrenergic receptor. Nature 281:114–117
Author information
Authors and Affiliations
Corresponding author
Additional information
Hoeren and Brawek contributed equally to this work.
Rights and permissions
About this article
Cite this article
Hoeren, M., Brawek, B., Mantovani, M. et al. Partial agonism at the human α2A-autoreceptor: role of binding duration. Naunyn-Schmied Arch Pharmacol 378, 17–26 (2008). https://doi.org/10.1007/s00210-008-0295-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-008-0295-6